Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
+$0.01 today
- Market cap
- $69.91M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
Volume 0.24M
Average 19.76M
GOSS Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Gossamer Bio, Inc.NASDAQ: GOSS
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 42.1% from a year ago
Net receivables stood at $9.35M at the end of Q1 FY2026, up 42.1% from a year earlier and down 25.3% from the prior quarter.
Context
- Net receivables amounted to 7.3% of total assets at the end of Q1 FY2026, up 4.9 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +42.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 12.53M USD
- Year-over-year change
- +134.7%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.53M | +134.7% |
| FY2024 | 2024-12-31 | 5.34M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How GOSS compares with its peers on the latest reported figures
- GOSS's Mar 2026 net receivables of $9.35M is the 5th highest of the 9 companies compared; the peer median is $7.15M.
- Its year-over-year change of +42.1% is the 3rd highest of 6, against a peer median of +20.2%.
- Net receivables amounts to 7.3% of total assets for GOSS, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $49.95M | +20.2% | +8.7% | 9.9% | |
| Mar 2026 | $11.78M | -75.2% | +339.9% | 4.4% | |
| Dec 2025 | $11.3M | — | — | 3.4% | |
| Mar 2026 | $10.94M | -42.9% | -3.3% | 3.2% | |
| Mar 2026 | $9.35M | +42.1% | — | 7.3% | |
| Mar 2026 | $3.35M | +74.5% | +133.4% | 0.6% | |
| Mar 2026 | $1.2M | +427.8% | -16.1% | 0.5% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding GOSS) | $7.15M | +20.2% | +8.7% | 1.9% | |
Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 183.4M | 111.97M | 32.11M | 46.07M | 37.73M |
| Short-term Investments | 141.82M | 143.71M | 264.32M | 248.44M | 99.2M |
| Net Receivables | 0 | 0 | 0 | 5.34M | 12.53M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 64K | 0 | 10.09M | 10.03M | 18.19M |
| Total Current Assets | 331.78M | 261.88M | 306.52M | 309.89M | 167.64M |
| Property, Plant & Equipment (Net) | 10.8M | 9.89M | 4.78M | 5.12M | 4.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.08M | 680K | 618K | 283K | 408K |
| Total Non-current Assets | 11.88M | 10.57M | 5.4M | 5.4M | 4.61M |
| Total Assets | 343.66M | 272.45M | 311.92M | 315.29M | 172.25M |
| Account Payables | 3.24M | 1.46M | 5.53M | 2.32M | 5.96M |
| Short-term Debt | 0 | 11.61M | 11.61M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 17.05M | 19.99M |
| Other Current Liabilities | 11.92M | 13.53M | 10.29M | 12M | 11.21M |
| Total Current Liabilities | 39.86M | 49.23M | 51.6M | 45.01M | 63.44M |
| Long-term Debt | 179.12M | 207.7M | 197.41M | 197.52M | 198.51M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 38.87M | 29.61M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 182.34M | 211.14M | 197.55M | 240.79M | 231.57M |
| Total Liabilities | 222.19M | 260.37M | 249.15M | 285.8M | 295.01M |
| Common Stock | 8K | 10K | 23K | 23K | 24K |
| Retained Earnings | (811.53M) | (1.03B) | (1.21B) | (1.27B) | (1.44B) |
| Accumulated OCI | 45K | (574K) | (350K) | 1.19M | (5.15M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 121.46M | 12.08M | 62.77M | 29.49M | (122.76M) |
| Total Debt | 185.24M | 225.74M | 212.46M | 202.88M | 202.91M |
| Net Debt | 1.83M | 113.77M | 180.36M | 156.81M | 165.17M |
Gossamer Bio, Inc.
NASDAQ:GOSS
Intrinsic Alpha fair value
Locked
Current Price
$11.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.